Last $52.19 USD
Change Today -1.80 / -3.33%
Volume 557.5K
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

cepheid inc (CPHD) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - $57.47
52 Week Low
07/31/14 - $36.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CEPHEID INC (CPHD)

cepheid inc (CPHD) Related Businessweek News

No Related Businessweek News Found

cepheid inc (CPHD) Details

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets; and for application in legacy non-clinical market. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also provides GeneXpert Infinity System for high volume testing. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. Cepheid sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; and Life Technologies Corporation to develop reagents for use in the USPS BDS program. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

1,200 Employees
Last Reported Date: 02/27/14
Founded in 1996

cepheid inc (CPHD) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $577.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $416.6K
President of Hbdc
Total Annual Compensation: $433.5K
Chief Regulatory Officer and Executive Vice P...
Total Annual Compensation: $352.5K
Compensation as of Fiscal Year 2013.

cepheid inc (CPHD) Key Developments

Cepheid and The Foundation For Innovative New Diagnostics Announce European Approval for HIV-1 Viral Load Test

Cepheid and the Foundation for Innovative New Diagnostics have announced CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices for Xpert HIV-1 Viral Load, a quantitative test for measurement of the HIV-1 viral load in plasma. The test runs on the Cepheid GeneXpert System. Xpert HIV-1 Viral Load is expected to begin shipping in February 2015.

Cepheid Announces Executive Changes Effective February 3, 2015

On December 30, 2014, Andrew Miller, Cepheid's Executive Vice President and Chief Financial Officer, who serves as Cepheid's principal financial and accounting officer, notified Cepheid that he will be leaving Cepheid to pursue an opportunity with PTC Inc. Mr. Miller's resignation will be effective February 3, 2015 and he will continue to serve as Cepheid's Chief Financial Officer until such time, directing Cepheid's financial operations and assisting with the upcoming transition. On December 30, 2014, Daniel Madden, currently Cepheid's Vice President and Corporate Controller, agreed to assume the role of principal financial and accounting officer effective February 3, 2015 until a new chief financial officer is appointed. Mr. Madden joined Cepheid as Vice President and Corporate Controller in June 2014. Prior to joining Cepheid, from November 2012 through January 2014, Mr. Madden served as Vice President Finance and Corporate Controller of Symmetricom Inc., which was acquired by Microsemi Corporation in November 2013. From March 2008 through November 2012, Mr. Madden served as Vice President, Finance and Investor Relations of Symmetricom Inc. Prior to that, from September 2005 through March 2008, Mr. Madden served as Vice President and Corporate Controller of Sonic Solutions.

Cepheid Receives FDA Clearance for Xpert Norovirus

Cepheid announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert(R) Norovirus, a qualitative in vitro diagnostic test for expeditious identification and differentiation of Noroviruses genogroup I (GI) and genogroup II (GII). Both Xpert Norovirus and the recently cleared Xpert Flu/RSV XC have also been categorized as Moderate Complexity tests. All Xpert tests run on Cepheid's GeneXpert(R) System. Norovirus is a highly contagious virus and is the most common cause of viral gastroenteritis worldwide. Noroviruses can be transmitted from an infected person, contaminated food or water, or by touching contaminated surfaces. Nausea, vomiting, watery diarrhea, and abdominal pain characterize infection.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPHD:US $52.19 USD -1.80

CPHD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Luminex Corp $17.75 USD -0.22
Meridian Bioscience Inc $17.75 USD -0.22
QIAGEN NV €20.06 EUR -0.63
Quidel Corp $24.36 USD -0.60
Sequenom Inc $3.59 USD -0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation CPHD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.4x
Price/Book 10.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEPHEID INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at